Novelty Nobility joins JLABS Korea

(Image credit: ©Valery/AdobeStock)

Novelty Nobility, a Korean antibody drug discovery company, recently announced it has been selected to join JLABS Korea.¹ JLABS, part of Johnson & Johnson’s global incubator network, supports startups in their efforts by offering access to expertise, development resources, strategic partnerships, as well as investor networks in the healthcare space.

Specializing in advanced modality antibody drugs, as part of JLABS Korea, Novelty Nobility will focus on developing two antibody candidates, according to a press release:

1. NN4101: a bispecific antibody candidate to target c-Kit and vascular endothelial growth factor (VEGF) for vascular retinal diseases
2. NN3206: an antibody-drug conjugate (ACD) candidate to target Pan-RAS-mutated solid tumors.

Park Sang-gyu, chief executive officer of Novelty Nobility, said in a press release the company will “leverage” JLABS Korea to “enhance the competitiveness of [the company’s] early-stage follow-up on pipeline in the global market.”

Specializing in advanced modality antibody drugs, Novelty Nobility’s pipeline targets therapeutic areas such as immune disorders, cancer and ophthalmic diseases that can utilize antibody treatments.

Two separate institutions awarded Novelty Nobility A grades in July 2024 in the technical evaluation for a special listing on Kasdaq. The company has also recently filed a preliminary listing application.

“We are committed to advancing our pipeline and achieving meaningful business outcomes through collaborative research with global pharmaceutical companies,” Sang-gyu said in a press release.

References:

1. Sook H. Novelty Nobility joins Johnson & Johnson’s JLABS Korea to advance antibody drug pipeline. KBR. Published April 8, 2025. Accessed April 9, 2025. https://www.koreabiomed.com/news/articleView.html?idxno=27206

‌